Avery Digital develops CMOS chip technology that enables bioengineers to design, build, and test millions of precision cellular variants rapidly, significantly reducing research timelines from months to hours. This platform facilitates high-throughput DNA synthesis and data generation, enhancing the efficiency of bioengineering and BioAI applications.
Funding
$480K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current bioengineering research is limited by the time and resources required to design, build, and test cellular variants, often taking months to complete a single iteration. This slow pace hinders the development of new biological systems and the application of BioAI.
Solution
Avery Digital offers a CMOS chip-based platform that accelerates the bioengineering workflow, enabling users to design, build, and test millions of cellular variants in hours instead of months. The platform supports high-throughput DNA synthesis and data generation, facilitating rapid experimentation and optimization. By leveraging CMOS technology, Avery Digital provides the scale, control, and speed necessary to advance BioAI and bioengineering applications. The platform allows for the synthesis and booting up of any DNA payload in cells or cell-free systems for screening and selection.
Target Audience
Avery Digital's primary customers are bioengineers and researchers in the fields of BioAI and synthetic biology who require high-throughput experimentation and rapid iteration cycles.
Features
- Massively multiplexed high-throughput platform for engineering biology
- CMOS chip technology enables rapid design, build, and test cycles
- Supports synthesis of oligos, genes, and chromosomes
- Generates massive data sets for machine learning applications
- Electrochemical CMOS DNA synthesizer